Title: Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells


Authors: Niradiz Reyes1,2, Ines Benedetti1,3, Juan Rebollo1,2, Oscar Correa2, Jan Geliebter4


Institutions: 1Department of Basic Sciences, School of Medicine, University of Cartagena, Cartagena, Bolívar, Colombia; 2Research Group of Genetics and Molecular Biology; 3Research Group of Histopathology; 4School of Medicine, Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA.


Abstract: Atypical chemokine receptors have recently emerged as important molecular players in health and diseases; they affect chemokine availability and function and impact a multitude of pathophysiological events, including the tumorigenesis process. This family of atypical receptors comprises five members: ACKR1/DARC, ACKR2/D6, ACKR3/CXCR7, ACKR4/CCRL1, and ACKR5/CCRL2. This work evaluated the differential expression of these receptors in prostate cancer using quantitative PCR. Further evaluation of CCRL2 at the protein level confirmed its overexpression in a metastatic cell line and in malignant prostatic tissues from patients. CCRL2, a presumed member of the atypical chemokine receptor family, plays a key role in lung dendritic cell trafficking to peripheral lymph nodes. Recent studies have reported the expression of CCRL2 in different human cancer cell lines and tissues. However, its function and expression in prostate cancer has not been previously addressed.


Keywords: chemokine receptor, prostatic neoplasms, CCRL2 receptor, real-time polymerase chain reaction, tissue array analysis


Full Text: JBR-2017-0057.pdf


J Biomed Res published on 05 January 2018, https://doi.org/10.7555/JBR.32.20170057